Abstract: Disclosed herein are methods and compositions for treatment and prevention of alopecia, including alopecia areata. Aspects are directed to methods for stimulating or accelerating hair follicle regeneration. Certain aspects are directed to methods for treating alopecia areata comprising administration of fibroblasts and/or a fibroblast derived product to a subject suffering from alopecia areata. In some cases, a fibroblast derived product is conditioned media, exosomes, or apoptotic bodies from fibroblasts, formulated for topical use for treatment or prevention of alopecia areata.

Abstract: Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Abstract: The present invention relates to the use of proteins, enzymes and probiotics to create a wholistic system that prevents negative effects of protein indigestion on gut microbiota and improves diversity and count of gut microbiota, thereby promoting microflora balance. The invention, in one or more embodiments, increases the bioavailability of postbiotics that regulate health, including, skin health, stress, anxiety and depression, physical endurance, healthy aging, inflammation and cardiac health. The invention, in one or more embodiments, also increases the bioavailability of essential, non-essential and branched amino acids.

Abstract: The invention relates to microbials for use in improving the health of a human and animals. More particularly, the invention relates to isolated Bacillus strains, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use, in particular for improving the gastrointestinal health of animals or humans.

Abstract: Provided is a composition for improving gut microbiota, including: a bacterial species combination consisting of Limosilactobacillus fermentum TCI275 with an accession number of BCRC 910940, Bifidobacterium animalis subsp. lactis TCI604 with an accession number of BCRC 910887, and Weizmannia coagulans TCI803 with an accession number of BCRC 910946. Provided is a method for improving gut microbiota of a subject in need thereof with the bacterial species combination.

Abstract: The present disclosure relates to a complex probiotic composition and a method for improving exercise performance of a subject with low intrinsic aerobic exercise capacity. The complex probiotic composition, which includes Lactobacillus rhamnosus GKLC1, Bifidobacterium lactis GKK24 and Clostridium butyricum GKB7, administered to the subject with the low intrinsic aerobic exercise capacity in a continuation period, can effectively reduce serum lactic acid and serum urea nitrogen after aerobic exercise, reduce proportion of offal fat and/or increase liver and muscle glycogen contents, thereby being as an effective ingredient for preparation of various compositions.

Abstract: Provided herein are methods and compositions for a probiotic composition comprising at least one probiotic strain selected based on gas production resulting from digestion of a specific food, food product, food ingredient or food component to reduce the amount of gas and or bloating produced when a subject consumes the specific food, food product, food ingredient, or food component.

Abstract: The present invention relates to a composition for use in the prevention of respiratory allergy, in particular allergic rhinitis, dust mite allergy and/or asthma in toddlers. The invention also provides a kit comprising a combination of at least one polyphenol and at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis in one or more containers.

Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.

Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.

Abstract: The present disclosure relates to hybrid hashish products comprising a cohesive mass of agglomerated isolated Cannabis trichomes and particles of Cannabis plant biomass, and methods for manufacturing same. The method includes providing pre-treated raw materials for making the hybrid hashish product, the raw materials comprising pre-treated isolated Cannabis trichomes and pre-treated Cannabis plant biomass, comprising a Cannabis oil layer on at least a portion of a respective surface thereof; and mixing the raw materials under conditions sufficient to obtain a cohesive mass of agglomerated isolated Cannabis trichomes and particles of the Cannabis plant biomass.

Abstract: A composition for the treatment of acne includes hydrolyzed Psoralea corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In various implementations, the composition is a water-based acne gel or a water-based cleanser. In a specific implementation, a composition includes Bakutrol(TM), which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid, benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.

Abstract: The present invention relates to compositions comprising a green coffee extract and a Lamiaceae extract (such as a rosemary extract), the use of these composition in treating cardiovascular conditions, in particular, cardiovascular conditions resulting from atherosclerosis and methods of making the compositions.

Abstract: In general, embodiments of the present invention provide antiviral essential oil compositions, and methods of making and using the same. Essential oil compositions can include one or more essential oils, such as thyme essential oil, oregano essential oil, and/or cinnamon essential, optionally in combination with one or more emulsifiers. Essential oil compositions can be in the form of an emulsion and have droplet sizes less than about 25 microns. The use of these compositions in organisms and systems provides beneficial antiviral effects, among others.

Abstract: The present invention relates to methods of orally administering water soluble extracts of spearmint to subjects in a therapeutically effective amount to attenuate retinal cell damage and other neural cell damage outside the central nervous system related to decreased supply of neurotrophins, namely Nerve Growth Factor (NGF) induced by glaucoma and other forms of neurodegeneration.

Abstract: An areca nut product and preparation method thereof, and an areca nut additive agent are provided. The areca nut product is prepared from areca nuts, citric acid, mature vinegar, chitosan, active zinc oxide, monazite calcined distilled water, bovine bone protein peptide, lipase, isomaltooligosaccharide, soybean lecithin, ginseng, atractylodes macrocephala, poria cocos, liquorice, astragalus, notoginseng, tangerine peel, folium eucommiae, citronella grass, and mucor. Experimental tests shows that the areca nut product of the disclosure has a good antiviral effect, and the areca nut product has good preventive and therapeutic effects on oral diseases; compared with ordinary areca nut products, carcinogenic study has shown that carcinogenicity of the areca nut product of the disclosure has significantly reduced.

Abstract: In one embodiment, the present application discloses, in part, biologically active compositions comprising a Crila® composition, or an admixture of Crinum latifolium L. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the Crinum latifolium L. dry extract to EGCG, and their use in the treatment of intramural or subserosal fibroids and various related diseases.

Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

Abstract: PROBLEM: To provide a hair growth agent which is a topical agent that exhibits effect in terms of causing increase in hair shaft diameter and improving maximum hair shaft length and improving hair shaft elongation rate and new hair growth and increasing expression of genes contributing to hair growth in dermal papilla cells and promoting hair shaft growth at head hair, beard, eyelashes, and/or eyebrows. SOLUTION MEANS: A hair growth agent which is a topical agent is made to contain active ingredient(s) in the form of palmitoyl dipeptide-5 diaminobutyloyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyrate, and/or adenosine.

Abstract: There is provided a drug which exhibits preventive and therapeutic effects on virus infectious diseases by inhibiting virus-derived protease on the basis of various physiological activity actions of an active sulfur compound(s) which exists in living organisms.

Abstract: The present disclosure relates to a ready-to-administer formulation of oxytocin, its pharmaceutically acceptable salts, or derivatives thereof, as well as products including the formulation. Specifically, the disclosure is directed to storage stable ready-to-administer formulations of oxytocin, method of producing such formulations and uses thereof.

Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.

Abstract: The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.

Abstract: The present invention relates to the field of biomedicine, and in particular to a use of goji glycopeptide in the preparation of a drug for preventing and/or treating amyotrophic lateral sclerosis. Experimental results prove the use of goji glycopeptide in the preparation of a drug for preventing and/or treating amyotrophic lateral sclerosis.

Abstract: The present disclosure relates to a stable aqueous composition of dalbavancin, the process for making such compositions and use of such compositions for treatment of a patient in need thereof.

Abstract: Use of an active ingredient in repairing heart tissue injury. Specifically, disclosed is an active ingredient capable of being used for repairing heart tissue injury and treating diseases related to lymphatic abnormalities, comprising: a TBX1 protein, a coding gene thereof, or an accelerator thereof, or a combination thereof. The TBX1 protein can promote the proliferation of heart lymphatic endothelium cells, play an immunoregulatory role, promote the establishment of an immunosuppressive microenvironment in the myocardium after heart tissue injury, inhibit autoimmune responses after the heart tissue injury, relieve concurrent inflammation of the heart tissue, and promote the repair and regeneration of the injured heart tissue.

Abstract: The present disclosure relates to use of a Dvl3-DEP peptide in the preparation of a medicament for repairing Sertoli cell injury in testes, and belongs to the technical field of medicine preparation. The Dvl3-DEP peptide is used in the preparation of a medicament for repairing Sertoli cell injury in testes, and the Dvl3-DEP peptide has an amino acid sequence shown in SEQ ID NO. 1. Tests prove that the overexpression of a Dvl3-DEP-coding gene significantly increases the level of cell resistance, repairs the tight junction function among Sertoli cells destructed by perfluorooctane sulphonate (PFOS) infection and enables a tight junction among Sertoli cells, and repairs the tight junction structure among Sertoli cells.

Abstract: Provided herein are compounds, trifunctional antibody products thereof, and methods and pharmaceutical compositions for use in treatment of inflammatory and/or proliferative diseases

Abstract: The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.

Abstract: The invention provides methods of treating a subject having diabetes mellitus and/or a metabolic derangement.

Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.

Abstract: Disclosed herein is a method of treating cardiomyocyte reperfusion injury associated with an ischemic myocardial event. The method includes administering to a subject in need thereof an effective amount of a abaloparatide to a subject in need thereof prior to performing reperfusion, concurrent with performing reperfusion, or both. Further provided is a method of treating cardiomyocyte reperfusion injury associated with cardiac transplant. The method includes contacting a donor heart with an effective amount of abaloparatide.

Abstract: The present invention relates to GPCR ligand collagen peptides produced through microbial fermentation, and in particular, to a method of preparing collagen peptides obtained by culturing a microorganism, peptides prepared by the method, and a composition including the peptide as an active ingredient; and a composition for improving intestinal function, relieving inflammation, and/or promoting wound healing, and a method of preparing the composition.

Abstract: Compositions for treatment of sensitive skin comprising a peptide mixture, collagen, a first polyol and a second polyol are disclosed herein. Also disclosed are methods of using said compositions for increasing collagen levels in skin and improving or reducing discomfort of sensitive skin in a subject in need thereof.

Abstract: The present disclosure is directed to the use of a uric acid lowering agent (UALA) to increase the effectiveness of interferon in a subject with a viral infection. The UALA may be administered in combination with interferon in a subject undergoing interferon therapy.

Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

Abstract: An antibacterial peptide P104 and a lysin LysP53 with broad-spectrum lytic activity and applications thereof are provided. The amino acid sequence of the antibacterial peptide P104 is shown as SEQ ID NO: 1, and the gene sequence of the antibacterial peptide P104 is shown as SEQ ID NO: 3. The amino acid sequence of the lysin LysP53 is shown as SEQ ID NO: 2, and the gene sequence of the lysin LysP53 is shown as SEQ ID NO: 4. The antibacterial peptide P104 and the lysin LysP53 have lytic activity against Gram-negative bacteria, such as Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli The lysin LysP53 can be subjected to soluble expression by Escherichia coli, and the activity of the lysin is high. Therefore, they have good application prospects in the research and development of anti-infective drugs.

Abstract: The present invention relates to pharmaceutical compositions of ACE2 Fc fusion proteins and therapeutic uses thereof, in particular in the treatment of infections with SARS-CoV-2.

Abstract: The invention relates to antigenic polypeptides derived from a naturally occurring R. microplus protein, and nucleic acids encoding such polypeptides. The polypeptides elicit an immune response which, in turn, produces detrimental effects in R. microplus feeding on vaccinated cattle. Thus, the present disclosure provides novel vaccines to protect cattle from R. microplus infestation.

Abstract: The present disclosure provides T-cell modulatory polypeptides (TMPs) comprising an AI peptide epitope, MHC class II polypeptides, one or more immunomodulatory polypeptides, a TGF-? polypeptide, and a masking polypeptide. A TMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have an autoimmune disease.

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

Abstract: The invention relates to immunogenic or vaccine compositions and their use in particular in the prevention or treatment of infectious or cancer disorders. More specifically, the immunogenic or vaccine compositions of the present invention comprises a ribonucleic acid (RNA) molecule comprising an open-reading frame encoding a fusion protein, wherein said fusion protein comprises or essentially consists of: (i) a first polypeptide domain comprising either a. an antigen or a fragment thereof comprising at least one epitope of said antigen, b. a peptide moiety comprising a single epitope of an antigen, or c. a plurality of peptide moieties, wherein each peptide moiety comprises an epitope of an antigen and wherein said peptide moieties are fused together, optionally via peptide linker, said first polypeptide domain being fused to (ii) a second polypeptide domain comprising a C4bp-derived oligomerization domain and a positively charged tail.

Abstract: The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

Abstract: The present invention discloses a vaccine comprising one or more of Dermatan sulfate-binding adhesin 1 of P. acnes (DsA1 polypeptide), Dermatan sulfate-binding adhesin 2 of P. acnes (DsA2 polypeptide), and putative iron-transport protein (PITP) polypeptide of P.

Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.

Abstract: Disclosed herein are methods for detecting and producing PoMV. Further, disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing PoMV. The compositions and methods include immunogenic portions of PoMV including entry proteins. In at least particular cases, a mutated version of a portion of the PoMV is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.

Abstract: The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced “delayed type-I interferon”, resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.

Abstract: The invention describes transdermal vaccines which contain ultrasound responsive particles comprising a polypeptide shell. The surface of the particle has one or more indentations which are generally able to entrap a gas bubble. The particles are capable of generating inertial cavitation on exposure to ultrasound. The particles can be delivered transdermally, and can comprise antigen protein and/or adjuvant within the particle structure. The particles are therefore useful in methods of vaccination using transdermal delivery routes.

Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.